Original InvestigationChanges in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial
Key Words
Abbreviations and Acronyms
Cited by (0)
The RE-LY (Randomized Evaluation of Long Term Anticoagulation Therapy) trial was funded by Boehringer Ingelheim, Germany. All authors received scientific support from Boehringer Ingelheim. Dr. Böhm is supported by the Deutsche Forschungsgesellschaft (KFO 196) and has received consulting/honoraria fees from Boehringer Ingelheim, Bayer, Servier, and Medtronic. Dr. Ezekowitz is a consultant for and/or has received consulting/honoraria fees from Boehringer Ingelheim, Pfizer, Sanofi, Bristol-Myers Squibb, Portola, Bayer, Daiichi-Sankyo, Medtronic, Aegerion, Merck, Johnson & Johnson, Gilead, Janssen Scientific Affairs, Pozen Inc., Amgen, Coherex, and Armetheon. Dr. Connolly has received consulting and research grants from Boehringer Ingelheim. Dr. Eikelboom has received consulting/honoraria fees from Bayer, Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb/Pfizer, Sanofi, Daiichi-Sankyo, and Eli Lilly. Dr. Hohnloser has received consulting/honoraria fees from Boehringer Ingelheim, Bayer, Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo, Sanofi, St. Jude Medical, Portola, Gilead, Medtronic, and Zoll. Dr. Schirmer has received a travel allowance/research funding/speakers honoraria from Boehringer Ingelheim. Dr. Yusuf has received research grants from Boehringer Ingelheim. Dr. Diener received honoraria for participation in clinical trials, contribution to advisory boards and oral presentations from Boehringer Ingelheim. Dr. Hijazi has received institutional research grants from Boehringer Ingelheim and Bristol-Myers Squibb/Pfizer. Dr. Wallentin has received research grants, consultancy and lecture fees, honoraria, and travel support from AstraZeneca, Bristol-Myers Squibb/Pfizer, and GlaxoSmithKline; research grants, consultancy and lecture fees, and honoraria from Boehringer Ingelheim; research grants and consultancy fees from Merck & Co.; and consultancy fees from Abbott, Athera Biotechnologies, and Regado Biosciences. Drs. Schumacher and Brueckmann are employees of Boehringer Ingelheim, Germany. Dr. Reilly is an employee of Boehringer Ingelheim, Pharmaceuticals, USA. Dr. Kratz has reported that he has no relationships relevant to the contents of this paper to disclose.